Showing results (91-100 of 169) with videos related to

Sort By:
Pageof 17
Radiation Research|November 2, 2007
Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiationMichael Epperly, Shunqian Jin, Suhua Nie, et al.
Critical Care Medicine|December 4, 2008
Ethyl pyruvate reduces the development of zymosan-induced generalized inflammation in miceRosanna Di Paola, Emanuela Mazzon, Tiziana Genovese, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 5, 2002
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammationLuis Ulloa, Mahendar Ochani, Huan Yang, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|February 21, 2017
Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trialLakhmir S Chawla, James A Russell, Sean M Bagshaw, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 17, 2004
Exogenous IL-6 inhibits acute inflammatory responses and prevents ischemia/reperfusion injury after intestinal transplantationKei Kimizuka, Atsunori Nakao, Michael A Nalesnik, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 31, 2005
The phase 2 enzyme inducers ethacrynic acid, DL-sulforaphane, and oltipraz inhibit lipopolysaccharide-induced high-mobility group box 1 secretion by RAW 264.7 cellsMeaghan E Killeen, Joshua A Englert, Donna Beer Stolz, et al.
Critical Care Medicine|September 22, 2007
Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted antioxidantsMitchell P Fink, Carlos A Macias, Jingbo Xiao, et al.
JAMA|December 11, 2002
Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trialHoward L Corwin, Andrew Gettinger, Ronald G Pearl, et al.
Vaccine|October 25, 2003
Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjectsAlan S Cross, Steven M Opal, John E Palardy, et al.
Journal of the American Society of Nephrology : JASN|August 21, 2012
Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRDKevin E Chan, H Shaw Warren, Ravi I Thadhani, et al.
Pageof 17